Transdermal clonidine application: long-term results in essential hypertension

Area of Science:

• Dermatology
• Cardiology
• Pharmacology

Background:

• Essential hypertension remains a significant global health concern.
• Transdermal drug delivery systems offer a continuous and controlled method for administering medications.
• Clonidine transdermal therapeutic system (clonidine-TTS) has been explored for managing hypertension.

Purpose of the Study:

• To evaluate the efficacy and safety of clonidine-TTS in patients with essential hypertension.
• To assess the incidence of adverse skin reactions associated with chronic clonidine-TTS use.

Main Methods:

• 32 patients with essential hypertension were treated with clonidine-TTS (0.1 or 0.2 mg/24 h) for 7 days per application.
• The study involved a mean observation period of 7 months.
• Patch testing was conducted to identify allergens in patients experiencing skin reactions.

Main Results:

• Clonidine-TTS reduced blood pressure to normal levels in 63% of patients.
• A high frequency of contact dermatitis (47%) was observed, with 11 patients discontinuing treatment due to severe skin reactions.
• Patch testing revealed clonidine as the allergen in 7 out of 8 tested patients.

Conclusions:

• Clonidine-TTS demonstrates efficacy in managing essential hypertension.
• The high incidence of allergic contact dermatitis to clonidine significantly limits its long-term use.
• Further research into alternative formulations or treatments may be warranted to mitigate skin reactions.